Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | SDCBP | O00560 | 1/20 | 0.37 |
| ▸ | SDC2 | P34741 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599009 | 0.89 | PPARG (0.42) | ATMACE | |
| SCHEMBL1062783 | 0.86 | SLC7A5 (0.38) | ATMHDAC1ACEHDAC6 | |
| SCHEMBL4599020 | 0.86 | SYK (0.40) | ATMMEN1KMT2AMAPTCTSS | |
| SCHEMBL4600319 | 0.86 | SYK (0.40) | ATMMEN1KMT2AMAPTCTSS | |
| SCHEMBL4600067 | 0.84 | CTRB1 (0.40) | MAPT | |
| SCHEMBL30510366 | 0.84 | CTRB1 (0.40) | MAPT | |
| SCHEMBL4600752 | 0.84 | CTRB1 (0.40) | MAPT | |
| SCHEMBL5407004 | 0.84 | CTRB1 (0.40) | MAPT | |
| SCHEMBL4612508 | 0.84 | MALT1 (0.43) | MEN1KMT2ACTSSCTSKKCNA5 | |
| SCHEMBL4600305 | 0.84 | PPARG (0.39) | KMT2ACTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3504197-B1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-11-17 | — | — | EP | disclosed |
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3423467-B1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-28 | — | — | EP | disclosed |
| EP-3504197-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-07-03 | — | — | EP | disclosed |
| EP-3423469-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-01-09 | — | — | EP | disclosed |
| EP-3423467-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-01-09 | — | — | EP | disclosed |
| US-20180371015-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-20180371016-A1 | TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2018036957-A1 | NEW TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HTRA1, HTR1A, HTR1E | ATM 3659/4885MEN1 995/4885KMT2A 541/4885 |
| US-11014963-B2 | Trifluoromethylpropanamide derivatives as HTRA1 inhibitors | HTRA1, HTR3E, HTR1F | ATM 4038/4885MEN1 1631/4885KMT2A 1252/4885 |
| US-20180371016-A1 | TRIFLUOROMETHYLPROPANAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HTRA1, HTR3E, HTR1F | ATM 4038/4885MEN1 1631/4885KMT2A 1252/4885 |
| US-20180371015-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HTRA1, HTR1A, HTR1E | ATM 3240/4885MEN1 1197/4885KMT2A 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.